[{"source": "https://www.youtube.com/feeds/videos.xml?channel_id=UCF9IOB2TExg3QIBupFtBDxg", "title": "Ivermectin or Molnupiravir", "description": "Link to featured video\nhttps://www.youtube.com/watch?v=ctwX1cz_-dw&t=323s\n\nLink to Wefwafwa\u2019s channel\nhttps://www.youtube.com/channel/UCzsLklGgOttU3Se-WGLp7ow\n(he needs more subscribers)\n\nLink to support Wefwafwa\u2019s work in Africa\npatreon:https://www.patreon.com/awmedicalvideos\n\nDrugs Shown to Inhibit SARS-CoV-2 in COVID-19 Disease: Comparative Basic and Clinical Pharmacology of Molnupiravir and Ivermectin\n \nhttps://austinpublishinggroup.com/pharmacology-therapeutics/fulltext/ajpt-v9-id1149.pdf\n\nhttps://www.linkedin.com/in/leslie-adesuyi-ajayi-md-phd-fbpharmacols-fwacp-69154a38/\n\nThere are still many nations where vaccines are not yet widely available, \n\nThere is a gradual shift in focus, to antiviral drugs, \n\nAdjunctive chemoprophylaxis\n\nActive treatment of new SARS-CoV-2 infections\n\nPost -vaccination breakthrough COVID-19 cases\n\nThe two ways to get new drugs\n\nDevelop novel antiviral drugs for SARS-CoV-2 \n\nRepurpose existing FDA -approved drugs to treat COVID-19\n\nIvermectin is the most studied \u201crepurposed\u201d medication globally, \n\nin randomized clinical trials, retrospective studies and meta- analyses. \n\nMolnupiravir and Ivermectin Anti-SARS- CoV-2 Mechanisms, Pharmacokinetics and Pharmacodynamics \n\nMolnupiravir is a broad spectrum antiviral agent against SARS- CoV-2, SARS-CoV,\n\nseasonal or pandemic influenza and MERS corona virus\n\nIvermectin is an FDA-approved, WHO essential drug used as broad spectrum antiparasitic, antibiotic \n\nand which has demonstrated broad spectrum antiviral activity against RNA viruses, including HIV, Zika, MERS corona virus\n\nThe FDA-approved drug ivermectin inhibits the replication of SARS-CoV-2 in vitro\n\nhttps://www.sciencedirect.com/science/article/pii/S0166354220302011\n\n5000-fold inhibition of SARS-CoV-2, (99.98% at 48 hours\n\nThe inhibitory concentration IC50 of Molnupiravir shows it to be a more potent anti-SARS-CoV-2 agent, compared to Ivermectin in vitro. \n\nBoth molnupiravir and ivermectin are well absorbed after oral dosing\n\nTmax of molnupiravir being 1-1.75 hours,\n\nWith a half life of 7 hours\n\nTmax of ivermectin is 4-6 hours\n\nVery long half life of 81-91 hours\nIvermectin, being lipophilic has a large volume of distribution\n\nIvermectin has the ability to accumulate in the lungs\n\nThe anti-SARS-CoV-2 actions, both of molnupiravir and ivermectin, are dose and concentration dependent\n\nMolnupiravir active metabolite (NHC-5\u2019 Triphosphate), acts as a competitive alternative substrate for viral RNA\n\ncausing viral mutagenesis or mutations, which leads to viral error catastrophe and extinction of replication\n\nThere is some concern about the safety of NHC -nucleoside triphosphate, which is also mutagenic to mammalian cells\n\nIvermectin, multifarious actions, \n\nBinding to SARS-CoV-2 spike protein S\n\nReducing cell entry via human ACE2 receptors \n\nReducing viral transcription\n\nInhibition of cytokine production and inflammation\n(not yet been shown for molnupiravir) \n\nComplimentary pharmacokinetics and pharmacodynamics of the drugs\n\nMay be additive or synergistic\n\nThis should be further investigated in anti-SARS- CoV-2 antiviral combination therapy.\n\nA combination of molnupiravir with Ivermectin putatively, in effects on RdRP or cytokine release. \n\nCost\n\nhttps://www.who.int/selection_medicines/committees/expert/21/reviews/Ivermectin_Review1.pdf\n\nThe cost for a package of 100 tablets of 3 mg ivermectin is $2.96.\n\nSay, 12mg per day for 5 days = $0.53\n\nSafety\n\nhttp://www.vigiaccess.org\n\nhttps://www.who-umc.org/vigibase/vigibase/\n\n \n\n \n\n \n\n\n\nEfficacy\n\nIvermectin\n\nhttps://pubmed.ncbi.nlm.nih.gov/34145166/\n\nFor deaths, average risk ratio 0.38, (62% benefit) (moderate-certainty evidence\n\nhttps://ivmmeta.com\n\nEarly treatment \n\nLate treatment\n \n\nProphylaxis\n \n\n\n \n\nhttps://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD015017.pub2/epdf/full\n\nMain results, Treating people in hospital with COVID-19\n\nWe don't know whether ivermectin compared with placebo or usual care, 28 days after treatment:\u2013 \n\nleads to more or fewer deaths\n\nworsens or improves patients' condition assessed by need for ventilation or oxygen\n\nincreases or reduces unwanted events\n\nPreventing COVID-19\n\nWe don't know whether ivermectin leads to more or fewer deaths compared with no drug", "link": "https://www.youtube.com/watch?v=hKa3EZqofNo", "date_published": "2021-10-05 00:00:00+00:00", "persistent": false, "user": null, "language": "en-US"}]